I2032
Monoclonal Anti-Insulin-Like Growth Factor Binding Protein-1 antibody produced in mouse
clone 33627.11, purified immunoglobulin, lyophilized powder
Sinónimos:
Anti-IGFBP-1
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Seleccione un Tamaño
500 μG
498,50 €
498,50 €
Precio de catálogo997,00 €Ahorre 50 %Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad
Seleccione un Tamaño
Cambiar Vistas
500 μG
498,50 €
About This Item
498,50 €
Precio de catálogo997,00 €Ahorre 50 %Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad
Productos recomendados
origen biológico
mouse
Nivel de calidad
conjugado
unconjugated
forma del anticuerpo
purified immunoglobulin
tipo de anticuerpo
primary antibodies
clon
33627.11, monoclonal
Formulario
lyophilized powder
reactividad de especies
human
técnicas
capture ELISA: suitable
neutralization: suitable
western blot: 1-2 μg/mL
isotipo
IgG1
Nº de acceso UniProt
temp. de almacenamiento
−20°C
modificación del objetivo postraduccional
unmodified
Información sobre el gen
human ... IGFBP1(3484)
Descripción general
The effects of insulin-like growth factors (IGF) are modulated by a family of insulin-like growth factor binding proteins 1-6. (IGFBPs -1-6). IGFBP-1 is secreted as an endocrine factor by liver, kidneys, decidua and in human amniotic fluid, but has the ability to signal in autocrine and paracrine fashion. Post-translational modifications such as ubiquitination, glycosylation and phosphorylation alter the activity of IGFBPs. Phosphorylation of IGFBP-1 is mainly mediated by Casein kinase I and II and cAMP-dependent protein kinases. IGFBP-1 alters the bioavailability of IGF in the serum by binding and sequestration so that a regulated amount id available to act on the target cells. The functions of IGFBP-1 are most important in the physiology of female reproductive system in mammals, for growth and development of the developing fetus
Monoclonal Anti-Human Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) recognizes recombinant human IGFBP-1. No cross-reactivity is seen with recombinant human IGFBP-2, IGFBP-3, and IGFBP-4.
Monoclonal Anti-Human Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) recognizes recombinant human IGFBP-1. No cross-reactivity is seen with recombinant human IGFBP-2, IGFBP-3, and IGFBP-4.
Especificidad
The biological activity is measured by its ability to neutralize recombinant human IGFBP-1 in the presence of recombinant human IGF-I.
Inmunógeno
purified recombinant human insulin-like growth factor binding protein 1, expressed in E. coli.
Aplicación
Anti- Insulin-Like Growth Factor Binding Protein-1 antibody may be used for immunoblotting at a working concentration of 1-2 μg/ml. For ELISA, a working concentration of 2 μg/ml may be used. The antibody is suitable for neutralization reactions (ND50 is 10-40 μg/ml).
Forma física
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline.
Cláusula de descargo de responsabilidad
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Equipo de protección personal
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
D J Fowler et al.
Human reproduction update, 6(5), 495-504 (2000-10-25)
Insulin-like growth factor-1 (IGFBP-1) is particularly important in human female reproductive physiology, where it is involved with other factors in a complex system which regulates menstrual cycles, puberty, ovulation, decidualization, implantation and fetal growth. This has implications for clinical obstetrics
Terry J Smith
Pharmacological reviews, 62(2), 199-236 (2010-04-16)
This topically limited review explores the relationship between the immune system and insulin-like growth factors (IGF-I and IGF-II) and the proteins through which they act, including IGF-I receptor (IGF-IR) and the IGF-I binding proteins. The IGF/IGF-IR pathway plays important and
K M Kelley et al.
The international journal of biochemistry & cell biology, 28(6), 619-637 (1996-06-01)
The IGFBPs are a family of homologous proteins that have co-evolved with the IGFs and that confer upon the IGF regulatory system both functional and tissue specificity. IGFBPs are not merely carrier proteins for IGFs, but hold a central position
M Westwood
Reviews of reproduction, 4(3), 160-167 (1999-10-16)
Insulin-like growth factors and their binding proteins are key regulators of fetal and maternal tissue growth and development during human pregnancy. Insulin-like growth factors, particularly IGF-II, are produced in abundance by the trophoblast cells of the placenta, whereas one of
Ali Vaziri-Gohar et al.
Molecular and cellular endocrinology, 422, 160-171 (2015-12-23)
Tamoxifen, a selective estrogen receptor modulator, is a commonly prescribed adjuvant therapy for estrogen receptor-α (ERα)-positive breast cancer patients. To determine if extracellular factors contribute to the modulation of IGF-1 signaling after tamoxifen treatment, MCF-7 cells were treated with IGF-1 in
Filtros activos
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico
